Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update. "We are ...

Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Kolschowsky Research and Education Institute at Sarasota Memorial Hospital is seeking candidates diagnosed with ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

Scientists uncovered how childhood BK virus infections may set off cancer-causing mutations decades later: by activating a host immune system enzyme that attacks DNA. When you purchase through links ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.

Statistics show a clear spike in eight cancers in younger people, but that has brought a debate over whether many cases ever needed to be found. By Gina Kolata The statistics are incontrovertible: ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content ...

Alyssa Tapley, 16, thought she was going to die of leukaemia before receiving the treatment A therapy that would once have been considered a feat of science fiction has reversed aggressive and ...

Solid Biosciences, valued at $463 million, will have updated Phase I/II Duchenne muscular dystrophy data in 2026, along with three FDA meetings in the first half of the year to finalize Phase III ...